CA3139156A1 - Compounds for the treatment of kinase-dependent disorders - Google Patents
Compounds for the treatment of kinase-dependent disorders Download PDFInfo
- Publication number
- CA3139156A1 CA3139156A1 CA3139156A CA3139156A CA3139156A1 CA 3139156 A1 CA3139156 A1 CA 3139156A1 CA 3139156 A CA3139156 A CA 3139156A CA 3139156 A CA3139156 A CA 3139156A CA 3139156 A1 CA3139156 A1 CA 3139156A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- kinase
- treatment
- dependent disorders
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856920P | 2019-06-04 | 2019-06-04 | |
| US62/856,920 | 2019-06-04 | ||
| PCT/US2020/035808 WO2020247418A1 (en) | 2019-06-04 | 2020-06-03 | Compounds for the treatment of kinase-dependent disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3139156A1 true CA3139156A1 (en) | 2020-12-10 |
Family
ID=71842789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3139156A Pending CA3139156A1 (en) | 2019-06-04 | 2020-06-03 | Compounds for the treatment of kinase-dependent disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12503438B2 (https=) |
| EP (1) | EP3980404A1 (https=) |
| JP (1) | JP7820152B2 (https=) |
| CN (1) | CN114040912B (https=) |
| AR (1) | AR119069A1 (https=) |
| AU (1) | AU2020289324B2 (https=) |
| CA (1) | CA3139156A1 (https=) |
| MA (1) | MA56114A (https=) |
| TW (1) | TWI850394B (https=) |
| WO (1) | WO2020247418A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| CN114573553B (zh) * | 2022-01-27 | 2023-11-10 | 广州六顺生物科技有限公司 | 杂芳环类衍生物及其制备方法和应用 |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
| CN116271008A (zh) * | 2022-12-30 | 2023-06-23 | 广东天普生化医药股份有限公司 | 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| JP2009526761A (ja) * | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| IL248408B (en) * | 2014-04-25 | 2022-06-01 | Exelixis Inc | A method for treating adenocarcinoma of the lungs |
| CN104817497B (zh) * | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
-
2020
- 2020-06-02 AR ARP200101554A patent/AR119069A1/es unknown
- 2020-06-03 AU AU2020289324A patent/AU2020289324B2/en active Active
- 2020-06-03 MA MA056114A patent/MA56114A/fr unknown
- 2020-06-03 US US17/616,120 patent/US12503438B2/en active Active
- 2020-06-03 JP JP2021571941A patent/JP7820152B2/ja active Active
- 2020-06-03 EP EP20747207.7A patent/EP3980404A1/en active Pending
- 2020-06-03 CN CN202080048050.0A patent/CN114040912B/zh active Active
- 2020-06-03 CA CA3139156A patent/CA3139156A1/en active Pending
- 2020-06-03 WO PCT/US2020/035808 patent/WO2020247418A1/en not_active Ceased
- 2020-06-04 TW TW109118785A patent/TWI850394B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022535108A (ja) | 2022-08-04 |
| US20230043835A1 (en) | 2023-02-09 |
| TW202110806A (zh) | 2021-03-16 |
| AU2020289324A1 (en) | 2021-12-16 |
| JP7820152B2 (ja) | 2026-02-25 |
| US12503438B2 (en) | 2025-12-23 |
| MA56114A (fr) | 2022-04-13 |
| AU2020289324B2 (en) | 2026-04-23 |
| AR119069A1 (es) | 2021-11-24 |
| EP3980404A1 (en) | 2022-04-13 |
| CN114040912A (zh) | 2022-02-11 |
| TWI850394B (zh) | 2024-08-01 |
| WO2020247418A1 (en) | 2020-12-10 |
| CN114040912B (zh) | 2024-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551208A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
| MX2022014351A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| CA3139156A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
| PH12021552759A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| ATE381332T1 (de) | Tyrosinkinase-hemmer | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| DE60208792D1 (de) | Tyrosin-kinase inhibitoren | |
| WO2004052315A3 (en) | Tyrosine kinase inhibitors | |
| EP1259235A4 (en) | TYROSINKINASE INHIBITORS | |
| EP1218376A4 (en) | Tyrosine kinase inhibitors | |
| EA201690391A1 (ru) | Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза | |
| EP1226119A4 (en) | TYROSIN KINASE INHIBITORS | |
| UA100262C2 (uk) | Інгібітори активності протеїнтирозинкінази | |
| WO2004052286A3 (en) | Tyrosine kinase inhibitors | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| EA201291055A1 (ru) | Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| EA202091790A1 (ru) | Соединения для лечения киназозависимых расстройств | |
| EA202091789A1 (ru) | Соединения для лечения киназозависимых расстройств | |
| TH149015A (th) | สารประกอบที่คุมกิจกรรมของ c-fms และ/หรือ c-kit และการใช้งานสำหรับสิ่งนั้น |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240530 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250605 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251002 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251203 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251203 |